Business Context and Reporting Period
This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on March 15, 2010. The report details a specific corporate transaction involving the exchange of preferred stock for common stock.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the specific stock exchange transaction:
- Common Stock Issued: 239,396 shares ($0.001 par value).
- Preferred Stock Surrendered: 123,400 shares of 6% Exchangeable Convertible Preferred Stock.
- Remaining Preferred Stock: 1,923,413 shares outstanding post-transaction.
Material Changes
The material change reported is the reduction of outstanding preferred stock and the corresponding increase in common stock due to a voluntary exchange initiated by a non-affiliate stockholder. The transaction was settled on March 16, 2010.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of general business risks. The transaction was executed under Section 3(a)(9) of the Securities Act of 1933, relying on an exemption from registration for exchanges between an issuer and existing security holders where no commission is paid.
Investor Verification Checklist
- Verify the correct registrant name is Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Confirm the settlement date of the stock exchange was March 16, 2010.
- Check subsequent filings for the updated total share count of common stock.
- Review the terms of the 6% Exchangeable Convertible Preferred Stock to understand the conversion ratio used in this exchange.